报价延迟最少15分钟:2026/06/06 22:22 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
15.95 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.36/-0.97
|
|
企业价值
94.04M
|
| 资产负债 |
|
每股账面净值
8.67
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
858.00K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operationsas a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. |
